Nitrogen‐Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post‐Translational Prenylation of GTP‐Binding Proteins, Including Ras

Bisphosphonates are currently the most important class of antiresorptive drugs used for the treatment of metabolic bone diseases. Although the molecular targets of bisphosphonates have not been identified, these compounds inhibit bone resorption by mechanisms that can lead to osteoclast apoptosis. Bisphosphonates also induce apoptosis in mouse J774 macrophages in vitro, probably by the same mechanisms that lead to osteoclast apoptosis. We have found that, in J774 macrophages, nitrogen‐containing bisphosphonates (such as alendronate, ibandronate, and risedronate) inhibit post‐translational modification (prenylation) of proteins, including the GTP‐binding protein Ras, with farnesyl or geranylgeranyl isoprenoid groups. Clodronate did not inhibit protein prenylation. Mevastatin, an inhibitor of 3‐hydroxy‐3‐methylglutatyl (HMG)‐CoA reductase and hence the biosynthetic pathway required for the production of farnesyl pyrophosphate and geranylgeranyl pyrophosphate, also caused apoptosis in J774 macrophages and murine osteoclasts in vitro. Furthermore, alendronate‐induced apoptosis, like mevastatin‐induced apoptosis, could be suppressed in J774 cells by the addition of farnesyl pyrophosphate or geranylgeranyl pyrophosphate, while the effect of alendronate on osteoclast number and bone resorption in murine calvariae in vitro could be overcome by the addition of mevalonic acid. These observations suggest that nitrogen‐containing bisphosphonate drugs cause apoptosis following inhibition of post‐translational prenylation of proteins such as Ras. It is likely that these potent antiresorptive bisphosphonates also inhibit bone resorption by preventing protein prenylation in osteoclasts and that enzymes of the mevalonate pathway or prenyl protein transferases are the molecular targets of the nitrogen‐containing bisphosphonates. Furthermore, the data support the view that clodronate acts by a different mechanism.

[1]  G. Blackburn,et al.  Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold dictyostelium discoideum , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  M. Wiley,et al.  Essential role for mevalonate synthesis in DNA replication. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Needle,et al.  Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. , 1992, Journal of lipid research.

[4]  W. Maltese Posttranslational modification of proteins by isoprenoids in mammalian cells , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  U. Lerner,et al.  Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro. , 1987, Bone.

[6]  M. Zerial,et al.  Rab GTPases in vesicular transport. , 1993, Current opinion in cell biology.

[7]  T. Martin,et al.  Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. , 1993, The Journal of clinical investigation.

[8]  F. Mollinedo,et al.  Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. , 1994, Biochemical and biophysical research communications.

[9]  J. Lawry,et al.  Bisphosphonates induce apoptosis in mouse macrophage‐like cells in vitro by a nitric oxide‐independent mechanism , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  P. Casey,et al.  Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.

[11]  L. Bonewald,et al.  Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. , 1990, The Journal of clinical investigation.

[12]  C. Der,et al.  Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes (*) , 1995, The Journal of Biological Chemistry.

[13]  G. Pluijm,et al.  23. The effect of dimethyl-APD (Me2APD) on migration and phenotypic transformation of osteoclast-precursors into mature osteoclasts , 1988 .

[14]  S. Narumiya,et al.  The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. , 1995, Journal of cell science.

[15]  J. Logel,et al.  Defective macromolecule biosynthesis and cell-cycle progression in a mammalian cell starved for mevalonate. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[16]  H. Fleisch,et al.  Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. , 1996, Endocrinology.

[17]  R. Schmidt,et al.  Evidence for post-translational incorporation of a product of mevalonic acid into Swiss 3T3 cell proteins. , 1984, The Journal of biological chemistry.

[18]  M. Ostad,et al.  Ha-ras oncogene expression abrogates a pH dependent endonuclease activity of apoptosis in normal rat kidney cells. , 1996, Cancer letters.

[19]  H. Väänänen,et al.  Endocytic pathway from the basal plasma membrane to the ruffled border membrane in bone-resorbing osteoclasts. , 1997, Journal of cell science.

[20]  G. Bilder,et al.  1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. , 1996, Arzneimittel-Forschung.

[21]  C. Marshall,et al.  All ras proteins are polyisoprenylated but only some are palmitoylated , 1989, Cell.

[22]  P. Schlesinger,et al.  Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. , 1990, The Journal of clinical investigation.

[23]  G. Rodan,et al.  Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. , 1991, The Journal of clinical investigation.

[24]  M. Gelb,et al.  Human lamin B contains a farnesylated cysteine residue. , 1989, The Journal of biological chemistry.

[25]  G. Prendergast,et al.  Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton , 1994, Molecular and cellular biology.

[26]  P. Casey,et al.  p21ras is modified by a farnesyl isoprenoid. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Nigg,et al.  The CaaX motif is required for isoprenylation, carboxyl methylation, and nuclear membrane association of lamin B2 , 1991, The Journal of cell biology.

[28]  H. Fleisch Bisphosphonates , 2012, Drugs.

[29]  A. Wyllie,et al.  Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability. , 1993, British Journal of Cancer.

[30]  T. Yoneda,et al.  Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  F. Mollinedo,et al.  Intracellular Alkalinization Suppresses Lovastatin-induced Apoptosis in HL-60 Cells through the Inactivation of a pH-dependent Endonuclease (*) , 1995, The Journal of Biological Chemistry.

[32]  G. van der Pluijm,et al.  Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: The effect of a bisphosphonate , 1988, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  J. Mönkkönen,et al.  Clodronate and Liposome‐Encapsulated Clodronate Are Metabolized to a Toxic ATP Analog, Adenosine 5′‐(β,γ‐Dichloromethylene) Triphosphate, by Mammalian Cells In Vitro , 1997 .

[34]  D. Samid,et al.  Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. , 1996, Molecular pharmacology.

[35]  Anne J. Ridley,et al.  The small GTP-binding protein rac regulates growth factor-induced membrane ruffling , 1992, Cell.

[36]  P. Delmas,et al.  MANAGEMENT OF PAGET’S DISEASE OF BONE , 1978 .

[37]  P. Croucher,et al.  Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activity , 1997, British journal of haematology.

[38]  R. Recker,et al.  Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis , 1996 .

[39]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[40]  P. Boonekamp,et al.  Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. , 1986, Bone and mineral.

[41]  N. Neamati,et al.  Degradation of lamin B1 precedes oligonucleosomal DNA fragmentation in apoptotic thymocytes and isolated thymocyte nuclei. , 1995, Journal of immunology.

[42]  P. Härkönen,et al.  Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. , 1996, Molecular pharmacology.

[43]  Anne J. Ridley,et al.  The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors , 1992, Cell.